CLINICAL_TRIALS
trial_result
· 2023-09-01
Clinical Trial Update: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) [EARLY_Phase 1]
Summary
Early-phase trial of Emerfetamab (AMG 673) in adults with relapsed/refractory acute myeloid leukemia was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Acute Myeloid Leukemia | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2023-09-01